Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 160,408	$ 154,901
Marketable securities	239,933	236,949
Accounts receivable, net of reserves of $4,909 in 2017 and $4,523 in 2016	225,353	204,494
Inventories	172,183	158,034
Other current assets	80,711	91,206
Total current assets	878,588	845,584
Long-Term Assets:
Property and equipment, net	361,233	357,422
Goodwill	180,601	178,228
Intangible assets, net	45,686	46,155
Other long-term assets	105,983	103,315
Total long-term assets	693,503	685,120
TOTAL ASSETS	1,572,091	1,530,704
Current Liabilities:
Accounts payable	62,249	60,057
Accrued liabilities	174,763	236,131
Line of credit	671,000	611,000
Current portion of deferred revenue	28,065	27,380
Total current liabilities	936,077	934,568
Long-Term Liabilities:
Deferred income tax liabilities	39,964	39,287
Long-term debt	594,868	593,110
Long-term deferred revenue, net of current portion	33,074	33,015
Other long-term liabilities	42,020	38,937
Total long-term liabilities	709,926	704,349
Total liabilities	1,646,003	1,638,917
Commitments and Contingencies (Note 13)
Stockholders’ Deficit:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 103,740 shares in 2017 and 103,341 shares in 2016	10,374	10,334
Additional paid-in capital	1,030,147	1,011,895
Deferred stock units: Outstanding: 225 units in 2017 and 231 units in 2016	5,552	5,514
Retained earnings	609,420	540,401
Accumulated other comprehensive loss	(38,379)	(43,053)
Treasury stock, at cost: 15,807 shares in 2017 and 15,367 shares in 2016	(1,691,204)	(1,633,443)
Total IDEXX Laboratories, Inc. stockholders’ deficit	(74,090)	(108,352)
Noncontrolling interest	178	139
Total stockholders’ deficit	(73,912)	(108,213)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,572,091	$ 1,530,704